Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Anticipated Size Of The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Over The Five-Year Period 2025–2029?
The poly (adp-ribose) polymerase (parp) inhibitors market has experienced swift expansion recently. Forecasts indicate it will expand from $6.53 billion in 2024 to $7.49 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.8%. This historical growth is linked to factors such as a rise in cancer cases, expanded genetic testing, greater success in clinical trials, broader insurance coverage, and enhanced cancer research efforts.
The poly (adp-ribose) polymerase (parp) inhibitors market is poised for significant expansion in the coming years. Projections indicate its size will reach $13.15 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 15.1%. This anticipated growth during the forecast period is primarily driven by factors such as increased drug production and supply, the escalating incidence of BRCA-mutated cancers, the rising prevalence of breast cancer, the expanded application of monoclonal antibodies, and increasing healthcare spending. Key trends influencing this market include progress in biomarker research, the emergence of combination therapies, the incorporation of artificial intelligence into drug development processes, strides in biomarker-driven therapy, and the creation of next-generation PARP inhibitors.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22102&type=smp
Which Drivers Are Shaping The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Industry’s Market Share?
The increasing incidence of breast cancer is anticipated to drive the expansion of the poly(ADP-ribose) polymerase (PARP) inhibitors market in the future. Breast cancer is defined as a condition where breast cells multiply without control, creating a malignant tumor capable of metastasizing to other bodily regions. This growing prevalence stems from factors including an aging global population, shifts in lifestyle, genetic susceptibilities, hormonal disruptions, obesity, alcohol intake, and heightened exposure to environmental hazards. PARP inhibitors offer therapeutic benefits to breast cancer patients by obstructing the PARP enzyme’s capacity to mend DNA damage within cancer cells, thereby inducing cell demise, especially in tumors possessing BRCA1 or BRCA2 mutations. For example, the National Breast Cancer Foundation, a US-based entity, reported in January 2025 that one in every eight women in the United States is projected to receive a breast cancer diagnosis at some point in her life. During 2024, 310,720 women and 2,800 men were diagnosed with invasive forms of breast cancer. Consequently, the increasing incidence of breast cancer is a key driver for the expansion of the poly(ADP-ribose) polymerase (PARP) inhibitors market.
What Are The Segment Types Shaping The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?
The poly (adp-ribose) polymerase (parp) inhibitorsmarket covered in this report is segmented –
1) By Type: Olaparib; Rucaparib; Niraparib; Talazoparib; Other Types
2) By Indication: Ovarian Cancer; Breast Cancer; Prostate Cancer; Pancreatic Cancer
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End-User: Hospitals; Specialty Clinics; Research Institutions; Other End-Users
Subsegments:
1) By Olaparib: BRCA-Mutated Cancers; HRD-Positive Cancers; Maintenance Therapy
2) By Rucaparib: Ovarian Cancer; Prostate Cancer; Pancreatic Cancer
3) By Niraparib: First-Line Treatment; Recurrent Cancer Treatment; Late-Stage Cancer
4) By Talazoparib: Breast Cancer; Germline BRCA-Mutated Tumors; Neoadjuvant Or Adjuvant Therapy
5) By Other Types: Emerging PARP Inhibitors; Investigational Therapies; Novel Combinations
Which Market Trends Are Creating New Opportunities In The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Industry?
Major companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are concentrating on developing advanced cancer treatments, specifically anticancer medicines, to target particular genetic mutations found in certain cancers. These medicines are utilized to combat cancer by either inhibiting the growth of cancer cells, preventing their spread, or destroying them, working through diverse mechanisms such as interfering with cell division, blocking specific proteins vital for tumor growth, or stimulating the immune system to fight the disease. For example, in March 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, introduced IBYRA, a generic version of the PARP inhibitor olaparib, in India. This drug offers an affordable and targeted treatment option for patients with HRD-positive and BRCA-positive cancers, significantly reducing treatment costs compared to the innovator drug.
Who Are The Major Companies Operating In The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?
Major companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Vertex Pharmaceuticals Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene LTD, Karyopharm Therapeutics Inc., Clovis Oncology Inc., Repare Therapeutics Inc., Ribon Therapeutics, Artios Pharma, IMPACT Therapeutics Inc., BiPar Sciences Inc., Allarity Therapeutics Inc.
Download The Full Report For Exclusive Market Findings:
How Is Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Demand Varying Across Different Regions?
North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/customise?id=22102&type=smp
Browse Through More Reports Similar to the Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market 2025, By The Business Research Company
Her2 Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report
Checkpoint Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report
Protein Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model